22179-85-7

Basic information

• Product Name: 4-Cyano-N-hydroxy-benzenecarboximidamide
• Synonyms: 4-Cyano-N-hydroxy-benzenecarboximidamide;4-CYANO-N-HYDROXYBENZENE-1-CARBOXIMIDAMIDE
• CAS NO: 22179-85-7
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16
• Product Categories: pharmacetical
• Mol File: 22179-85-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 393.6°Cat760mmHg
• Flash Point: 191.9°C
• Appearance: /
• Density: 1.25g/cm³
• CAS DataBase Reference: 4-Cyano-N-hydroxy-benzenecarboximidamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-N-hydroxy-benzenecarboximidamide(22179-85-7)
• EPA Substance Registry System: 4-Cyano-N-hydroxy-benzenecarboximidamide(22179-85-7)

Safety Data

• Hazardous Substances Data: 22179-85-7(Hazardous Substances Data)

Upstream product

• 123476-70-0 (Z)-4-cyano-N-hydroxybenzimidoyl chloride 
• 623-26-7 terephthalonitrile 

Downstream Products

• 873009-55-3 C₁₅H₁₆N₄O₃ 
• 844498-81-3 4-(5-chloromethyl-[1,2,4]oxadiazol-3-yl)-benzonitrile 
• 844498-79-9 C₁₀H₈ClN₃O₂ 
• 478489-09-7 5-(3-Chloro-thiophen-2-yl)-3-(4-cyano-phenyl)-[1,2,4]-oxadiazole 

Relevant articles and documents

FACTOR XA INHIBITORS

The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.